US2021188926A1PendingUtilityA1
Methods and compositions for genome engineering
Est. expiryDec 9, 2033(~7.4 yrs left)· nominal 20-yr term from priority
C12N 15/86A61P 7/04C07K 2319/81C07K 14/4702A61P 3/00C12N 2750/14142C12N 2750/14133C12N 9/22A61K 48/00C12N 2750/14143A61P 43/00C12N 9/644C07K 14/47
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A pharmaceutical composition comprising one or more polynucleotides encoding a pair of zinc finger nucleases (ZFNs) that cleave an endogenous albumin gene, each zinc finger nuclease comprising a cleavage domain and a zinc finger protein (ZFP) that binds to a target site in the endogenous albumin gene, wherein the zinc finger proteins of the pair are selected from the group consisting of a left ZFP designated SBS #47171, 47192, 47863, or 47864, the left ZFP comprising five recognition helix regions ordered F1 to F5 as shown in a single row of the following Table:
SBS#
F1
F2
F3
F4
F5
47171
QSGNLSR
LKQNLCM
WADNLQN
TSGNLTR
RQSHLCL
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 23)
NO: 18)
NO: 24)
NO: 20)
NO: 21)
47863
QSGNLAR
LIQYLQS
WADNLQN
TSGNLTR
RQSHLSL
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 2)
NO: 26)
NO: 24)
NO: 20)
NO: 27)
47192
QSGNLAR
LIQYLQS
WADNLQN
TSGNLTR
RQSHLCL
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 2)
NO: 26)
NO: 24)
NO: 20)
NO: 21)
47864
QSGNLAR
LIQYLQS
WQSNLQN
TSGNLTR
RQSHLCL
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 2)
NO: 26)
NO: 19)
NO: 20)
NO: 21)
and a right ZFP designated SBS #40477, 47079, 47169, 47898 or 47931, the right ZFP comprising six recognition helix regions ordered F1 to F6 as shown in a single row of the following Table:
SBS#
F1
F2
F3
F4
F5
F6
47931
TPQLLDR
LKWNLRT
DQSNLNA
RNFSLTM
LRHDLDR
HRSNLNK
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 14)
NO: 9)
NO: 25)
NO: 15)
NO: 16)
NO: 12)
47079
TPQLLDR
LKWNLRT
DQSNLRA
RNFSLTM
LRHDLDR
HRSNLNK
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 14)
NO: 9)
NO: 10)
NO: 15)
NO: 16)
NO: 12)
47898
TPQLLDR
LKHNLLT
DQSNLNA
RNFSLTM
LRHDLDR
HRSNLNK
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 14)
NO: 28
NO: 25)
NO: 15)
NO: 16)
NO: 12)
47169
TPQLLDR
LKWNLRT
DQSNLRA
RNFSLTM
LRHDLDR
HRSNLNK
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 14)
NO: 9)
NO: 10)
NO: 15)
NO: 16)
NO: 12)
40477
QSSDLSR
LKHNLLT
LKHNLLT
RPYTLRL
LRPDLER
HRSNLNK
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID
NO: 8)
NO: 28)
NO: 28)
NO: 11)
NO: 41)
NO: 12)
2 . The pharmaceutical composition of claim 1 , wherein the cleavage domain is an engineered cleavage domain.
3 . The pharmaceutical composition of claim 1 , wherein the one or more polynucleotides are viral or non-viral vectors.
4 . The pharmaceutical composition of claim 3 , wherein the polynucleotides encoding the first and second zinc finger nucleases are carried on the same or on different vectors.
5 . The pharmaceutical composition of claim 3 , wherein the viral vector is an AAV vector.
6 . The pharmaceutical composition of claim 5 , wherein the AAV vector is an AAV2/8 vector.
7 . The pharmaceutical composition of claim 1 , further comprising a donor polynucleotide comprising a transgene and the transgene is integrated into the endogenous albumin gene following cleavage by the pair of ZFNs.
8 . The pharmaceutical composition of claim 7 , wherein the donor polynucleotide is carried on an AAV vector.
9 . The pharmaceutical composition of claim 7 , wherein the transgene encodes one or more proteins lacking in a lysosomal storage disease.
10 . The pharmaceutical composition of claim 9 , wherein the protein is a glucocerebrosidase, an α galactosidase, an iduronate-2-sulfatase and/or an alpha-L iduronidase protein.
11 . The pharmaceutical composition of claim 7 , wherein the transgene encodes one or more clotting factors.
12 . The pharmaceutical composition of claim 11 , wherein the clotting factor is Factor IX (F.IX) protein, a Factor VII protein and/or a Factor X protein.
13 . A method of treating a lysosomal storage disease in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 7 to the subject.
14 . A method of treating a clotting disorder in a subject in need thereof, the method comprising administering the pharmaceutical composition of claim 11 to the subject.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.